These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1104 related articles for article (PubMed ID: 27795431)

  • 21. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.
    Wills S; Hwang KK; Liu P; Dennison SM; Tay MZ; Shen X; Pollara J; Lucas JT; Parks R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Thomas R; Kim JH; Michael NL; Robb ML; McRaven M; Montefiori DC; Hope TJ; Liao HX; Moody MA; Ferrari G; Haynes BF; Alam SM; Bonsignori M; Tomaras GD
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
    Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
    Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
    Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
    van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.
    Sips M; Krykbaeva M; Diefenbach TJ; Ghebremichael M; Bowman BA; Dugast AS; Boesch AW; Streeck H; Kwon DS; Ackerman ME; Suscovich TJ; Brouckaert P; Schacker TW; Alter G
    Mucosal Immunol; 2016 Nov; 9(6):1584-1595. PubMed ID: 26883728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
    Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
    Forthal DN; Gilbert PB; Landucci G; Phan T
    J Immunol; 2007 May; 178(10):6596-603. PubMed ID: 17475891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.
    Kim S; Filsinger Interrante MV; Kim PS
    J Virol; 2023 Jan; 97(1):e0164722. PubMed ID: 36541800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
    Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
    PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
    Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
    Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
    Frankel SS; Steinman RM; Michael NL; Kim SR; Bhardwaj N; Pope M; Louder MK; Ehrenberg PK; Parren PW; Burton DR; Katinger H; VanCott TC; Robb ML; Birx DL; Mascola JR
    J Virol; 1998 Dec; 72(12):9788-94. PubMed ID: 9811714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.